Policy

Patt: Payers Could Save More With Biosimilars

September 25, 2020

Tony Hagen

Article

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.

Report: Prescription Drug Costs Can Be Lowered Without Legislation

September 23, 2020

Skylar Jeremias

Article

Much emphasis is placed on the value of congressional action to reduce prescription costs, but the Center for American Progress suggests there is an existing toolkit to accomplish this objective.

Report: Lack of Biosimilar Competition Contributed to Billions in Lost Savings

September 21, 2020

Skylar Jeremias

Article

The United States has missed out on almost $20 billion in savings as a result of not having a competitive biosimilar market, according to findings from the Pacific Research Institute.

ACR Survey Reveals Patient Knowledge Gaps on Biosimilars

September 16, 2020

Skylar Jeremias

Article

Many patients with rheumatic diseases are unsure whether their prescriptions are biosimilars, suggesting more efforts in patient education are needed.

Expert Opinion Roundup: Overcoming Barriers to Biosimilar Uptake

September 7, 2020

Skylar Jeremias

Article

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.

Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs

September 3, 2020

Video

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.

Samsung Bioepis Exec Discusses European On-Ramp for Aybintio

September 3, 2020

Tony Hagen

Article

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

Report: OOP Insulin Caps Could Save Money, but Other Factors Bear Watching

September 3, 2020

Skylar Jeremias

Article

Authors of a report on Medicare spending trends said there’s more to controlling the affordability of insulin than instituting out-of-pocket (OOP) caps.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2, 2020

Tony Hagen

Article

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Midwest Business Group on Health Issues Call to Action on Biosimilars

August 28, 2020

Skylar Jeremias

Article

To help employers achieve biosimilar savings, the Midwest Business Group on Health has created a 13-step action plan.

x